The Company also plans to submit for an emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) to expand the authorized use of its vaccine to adolescents.
USA biotech firm Moderna said on Monday it was seeking conditional approval for use of its COVID-19 vaccine on teens in the European Union and Canada, in a boost for inoculation campaigns as the summer begins.
Moderna has received emergency (or other conditional, interim or provisional) authorization for use of its COVID-19 vaccine in adults from health agencies in the U.S., Canada, Israel, the European Union, the United Kingdom, Switzerland, Singapore, Qatar, Taiwan, the Philippines, Thailand, Brunei, Paraguay, Japan, South Korea, Botswana and an Emergency Use Listing (EUL) from the World Health Organization (WHO).
On June 3, Provincial Health Officer Dr. Bonnie Henry announced the Province will proceed with offering patients who received their first COVID-19 immunization of an AstraZeneca vaccine to have either a second dose of AstraZeneca or one of the two mRNA vaccines now available in B.C. - Pfizer/BioNTech and Moderna.
In adolescents, two doses of Moderna's mRNA vaccine were shown to be 100 percent effective at preventing illness from COVID-19 in a 2,500-participant trial.
Moderna has also filed for authorization to use its vaccine under emergency use regulations in the USA and Canada. Cumulatively, 3,02,45,100 persons in the age group across states and Union Territories have received their first dose and 2,37,107 the second dose since the start of phase-3 of the vaccination drive on May 1, the ministry said.
But extremely rare cases of severe COVID can still occur, as can a post-viral complication called multisystem inflammatory syndrome.
The vaccine was "generally well tolerated" among adolescents, the company said, adding: "No significant safety concerns have been identified to date".